Inscrivez-vous à notre newsletter

DPNI
DEPISTAGE PRENATAL

Dépistage prénatal noninvasif pour plus de précision

APERÇU

Plus de femmes méritent l'accès au DPNI

Etendez vos connaissances à l’aide d’une variété de ressources destinées aux professionnels (articles, matériel éducatif, webinaires…).

205973 (132850) cfDNA_Landscape-01

Des réponses précoces

Le dépistage prénatal non-invasif (DPNI) consiste à analyser l’ADN libre circulant (cfDNA) dans le sang maternel afin de détecter les anomalies chromosomiques fœtales. Le dépistage peut-être réalisé dès la 10ème semaine de grossesse.

Molécule d'ADN à l'intérieur d'un tube

Sûr et précis

A partir d’un simple prélèvement sanguin, le dépistage prénatal non-invasif permet d’obtenir de façon sure et précoce des résultats fiables, et contribue à réduire le nombre de procédures invasives inutiles.

Close-up Of A Person's Hand Stamping With Approved Stamp On Document At Desk

Reconnaissance internationale

Les sociétés scientifiques internationales ont reconnu l’analyse de l’ADN libre circulant comme la méthodologie la plus sensible et spécifique pour le dépistage des aneuploidies fétales les plus communes, et recommandent qu’elle soit offerte à toutes les femmes enceintes.1,2

RESSOURCES POUR LE DEPISTAGE PRENATAL NONINVASIF

Opinions d'Experts & Ressources

Etendez vos connaissances à l’aide d’articles, de matériel éducatif, de nouvelles et de wébinaires destinés aux professionnels.

Minimizing Patients’ Risk of Adverse Outcomes in NIPT
Webinar

Minimizing Patients’ Risk of Adverse Outcomes in NIPT

Lawrence Prensky, MS, LCGC, CCGC, discusses the challenges within NIPT on one of the biggest stages in prenatal health, the CoGEN 2020 World Conference.
Universal access to NIPT: Cost-effective and precise cell-free DNA testing
Webinar

Universal access to NIPT: Cost-effective and precise cell-free DNA testing

This PerkinElmer satellite symposium organized at the European Society of Human Genetics (ESHG) Virtual Conference 2020 presents two laboratories’ experience with Vanadis® NIPT, an automated, non-sequencing cell-free DNA testing platform. Speakers include Dr. Alka Chaubey (PerkinElmer Global Genomic, USA) and Prof. Barbara Pasini (University of Turin, Italy).
Making NIPT accessible to all women
Webinar

Making NIPT accessible to all women

This webinar aims to address some of the obstacles that have prevented the widescale adoption of NIPT. Issues such as: cost, focus, precision and ease of use will all be examined by our speakers and then reevaluated using PerkinElmer's new Vanadis® NIPT platform. Speakers include Prof. Howard Cuckle (Tel Aviv University, Israel) and Dr Alka Chaubey (PerkinElmer Global Genomic, USA)
Implementation and Validation of a High-Precision, Non-NGS NIPT Platform
Webinar

Implementation and Validation of a High-Precision, Non-NGS NIPT Platform

This Genomeweb webinar provides a comprehensive overview of Vanadis® NIPT system, an automated, high-precision non-invasive prenatal testing platform. Speakers: Dr. Glenn Palomaki (Women & Infants Hospital, Rhode Island, USA) and Dr Jérémie Gautier (Cerba Xpert, France).
A Case of SMA with Pompe Disease in India
Webinar

A Case of SMA with Pompe Disease in India

In a recent case in India, a child was diagnosed with simultaneous Pompe disease and spinal muscular atrophy (SMA). See Dr. Priyanshu Mathur’s presentation to learn more about the rare case and how the child was identified for treatment.
Newborn screening for LSDs – a pilot study from Brazil
Webinar

Newborn screening for LSDs – a pilot study from Brazil

Early diagnosis of lysosomal storage disorders is essential for better patient outcomes. In her presentation, Dr. Francyne Kubaski of the Medical Genetics Service of Brazil shares the learnings from an LSD newborn screening pilot study using tandem mass spectrometry. The study was conducted using PerkinElmer’s NeoLSD ™ MSMS kit, which enables screening of up to six lysosomal storage disorders from a single blood spot punch. See the video to learn more.
Genomic sequencing in newborns – yes or no?
Webinar

Genomic sequencing in newborns – yes or no?

It’s technically possible to produce high-quality genomic sequencing data from blood spot cards used in newborn screening. However, there are cost considerations, ethical issues as well as limitations in infrastructure and human resources to delivering genomic sequencing at scale. What additional value would genomic sequencing bring to newborn screening? For fresh insights, see the presentation by Professor John Christodoulou of the University of Melbourne Department of Paediatrics.
Molecular testing in newborn screening: how far we’ve come
Webinar

Molecular testing in newborn screening: how far we’ve come

In her presentation, Professor Mei Baker of the University of Wisconsin Department of Pediatrics discusses the state of molecular testing in newborn screening. Wisconsin’s screening program covers 47 disorders, including hemoglobinopathies, fatty acid disorders, amino acid disorders and the latest addition, Spinal Muscular Atrophy (SMA). Click below to learn some of the latest results and insights in molecular testing.
How do you keep your newborn screening program running under COVID-19 pressure?
Webinar

How do you keep your newborn screening program running under COVID-19 pressure?

Under these extraordinary circumstances, it takes some creative maneuvering to keep your newborn screening program going efficiently. Professor Carmencita Padilla of the University of the Philippines shares the lessons learned from the creative strategies and continuity plans implemented throughout the Philippine newborn screening program. See her presentation for practical advice and ideas on how to run your program under COVID-19 pressure.
Performance of commercially available placental growth factor tests in women with suspected preterm pre‐eclampsia; the COMPARE study
Peer-reviewed article

Performance of commercially available placental growth factor tests in women with suspected preterm pre‐eclampsia; the COMPARE study

F.P. McCarthy et. al. Ultrasound in Obstetrics & Gynecology
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit
Peer-reviewed article

Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit

David Wright et. al. The American Journal of Obstetrics & Gynecology
Aspirin versus Placebo in Pregnancies at high Risk for Preterm Preeclampsia
Peer-reviewed article

Aspirin versus Placebo in Pregnancies at high Risk for Preterm Preeclampsia

Daniel L. Rolnik et. al. The New England Journal of Medicine
Système DPNI Vanadis®

Système DPNI Vanadis®

Une solution de DPNI intégralement automatisée et rentable qui permette l'analyse ciblée de l'ADNc sans PCR, ni séquençage.
Multiplex Real-time PCR Newborn Screening Assay to Simultaneously Identify Spinal Muscular Atrophy and Severe Combined Immunodeficiency
Webinar

Multiplex Real-time PCR Newborn Screening Assay to Simultaneously Identify Spinal Muscular Atrophy and Severe Combined Immunodeficiency

Professor Mei Baker discusses Identifying Spinal Muscular Atrophy and Severe Combined Immunodeficiency using Real-time PCR newborn screening
PlGF and assessment of placental function in the first and third trimesters of pregnancy
Webinar

PlGF and assessment of placental function in the first and third trimesters of pregnancy

Professor Jon Hyett, Head of High-Risk Obstetrics and a Senior Staff Specialist in Obstetrics, and Maternal and Fetal Medicine Royal Prince Alfred Hospital, Sydney, Australia
First SMA baby identified with our screening solutions in Australia
Article

First SMA baby identified with our screening solutions in Australia

A newborn baby has been identified as having SMA (spinal muscular atrophy) in Westmead Children’s Hospital in Australia, using a 4-plex SMA, SCID and XLA laboratory developed test
Plus de Ressources
TESTS DISPONIBLES

Ce que vous pouvez dépister

Contrairement aux plateformes de dépistage basées sur le séquençage de nouvelle génération, complexes et onéreuses, le système de DPNI Vanadis permet un dépistage rentable et de haute précision des aneuploïdies fœtales. Rendre le DPNI accessible à plus de laboratoires et plus de femmes. Vanadis est conçu pour tous.

Common Trisomies

Trisomy 21 (Down syndrome)

Down syndrome, also called trisomy 21, is associated with the presence of an extra copy of chromosome 21. It is the most common chromosomal disorder in liveborn children and, although typically random, does occurs more commonly in the offspring of women as they get older.
En savoir plus
Common Trisomies

Trisomy 18 (Edwards syndrome)

Edwards syndrome, also called trisomy 18, is a chromosomal disorder associated with the presence of an extra chromosome 18. It is the second most common autosomal trisomy among liveborn children.
En savoir plus
Common Trisomies

Trisomy 13 (Patau syndrome)

Patau syndrome, also called trisomy 13, is a chromosomal disorder caused by the presence of an extra chromosome 13 in all or some of the cells.
En savoir plus
PLATEFORMES DE DEPISTAGE

Plateforme Vanadis® NIPT: Conçue pour tous

Contrairement aux plateformes de dépistage basées sur le séquençage de nouvelle génération, complexes et onéreuses, le système de DPNI Vanadis permet une dépistage rentable et de haute précision des aneuploidies fétales. Rendre le DPNI accessible à plus de laboratoires et plus de femmes. Vanadis est conçu pour tous.

facile

Facile

précis

Précis

économique

Rentable

NOS SOLUTIONS LES PLUS POPULAIRES

Produits Phare

Système DPNI Vanadis®

Système DPNI Vanadis®

Une solution de DPNI intégralement automatisée et rentable qui permette l'analyse ciblée de l'ADNc sans PCR, ni séquençage.
En savoir plus

Autres solutions pour le dépistage prénatal

Tenez-vous informé des dernières nouvelles relatives au dépistage prénatal noninvasif

shutterstock_364954436

Gestion de la pré-éclampsie (contenu anglais)

En savoir plus
Photo d'un corps de femme enceinte avec les mains sur son ventre

Dépistage sérique (contenu anglais)

En savoir plus
shutterstock_1689772501 1
NOUS CONTACTER

Inscrivez-vous à notre newsletter

Tenez-vous informé des dernières nouvelles relatives au dépistage prénatal noninvasif

S'inscrire
NOUS CONTACTER

Pour aller plus loin

Parlez à un vendeur

Discutez avec l’un de nos experts produits des solutions qui vous conviennent.

Contactez-nous aujourd'hui

Consultez plus de ressources

Explorer notre sélection d’articles et de documents pour en savoir plus sur nos solutions.

En savoir plus

Lisez les dernières nouvelles

Inscrivez-vous à notre newsletter pour découvrir les dernières nouvelles de PerkinElmer et de l’industrie.

En savoir plus

Références

  1. Practice Bulletin Number 226: Screening for fetal chromosomal abnormalities. Obstet Gynecol. 2020; 136(4)
  2. Benn P, Borrell A, Chiu R, et al. Position statement from the Chromosome Abnormality Screening Committee. Prenat Diagn. 2015;35(8):725-734.

Les produits peuvent ne pas être homologués selon les lois en vigueur dans chaque pays, notamment aux États-Unis et au Canada. Veuillez contacter votre représentant local afin de vérifier la disponibilité des produits dans votre pays.